Therefore, targeting the optimal tissue for activation or inhibition of FoxO1 and developing strategies for tissue-specific delivery of FoxO1 therapeutics could effectively treat T2D and minimize adverse side effects. This evidence concerns the gene FOXO1 and type 2 diabetes mellitus.